Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
January 2019
-
Featured NewsNovartis 2018 Financial ResultsNovartis CEO Vas Narasimhan announced the company’s fourth quarter and 2018 full year results.
-
Key ReleaseEn 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entrepriseHausse du chiffre d'affaires net de 5% (tcc[1], +6% USD) en 2018, soutenue par l'excellente performance des moteurs de croissance: Pharmaceuticals: cette unité opérationnelle a progressé de 7% (…
-
Key ReleaseNovartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das UnternehmenDer Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit…
-
Key ReleaseNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0…
-
In The NewsFortune's Most Admired Pharmaceutical Companies 2019Novartis ranks #4 in Fortune Magazine’s Most Admired Companies Pharmaceutical Industry list.
-
In The NewsThe Science and Business of Innovative MedicinesIn this a16z podcast, bio general partners Jorge Conde and Vijay Pande with Sonal Chokshi interview Vas Narasimhan, CEO of Novartis, on some questions, challenges and opportunities that we’re facing…
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell diseaseCrizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are…
-
Media ReleaseSandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use DisorderreSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a…
-
Flexibility at Novartis: Peter Canavan
Canavan describes how flexible working positively impacts his team.
-
Flexibility at Novartis: Deepti Mittal
Mittal shares how flexible working helped her and her family get through a difficult time.
Pagination
- ‹ Previous page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- …
- 152
- › Next page